

- 7A In Memoriam: Dirk J. Kwekkeboom (1958–2017)**  
*Lisa Bodei*
- 1S Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview**  
*Ken Herrmann, Steven M. Larson, and Wolfgang A. Weber*
- 3S Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine**  
*Rachel Levine and Eric P. Krenning*
- 10S Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications**  
*Jean Claude Reubi and Helmut R. Maecke*
- 17S Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers**  
*Klaus Kopka, Martina Benešová, Cyril Bařinka, Uwe Haberkorn, and John Babich*
- 27S Identification of Ligands and Translation to Clinical Applications**  
*Uwe Haberkorn, Walter Mier, Klaus Kopka, Christel Herold-Mende, Annette Altmann, and John Babich*
- 34S Iodine Symporter Targeting with  $^{124}\text{I}/^{131}\text{I}$  Theranostics**  
*James Nagarajah, Marcel Janssen, Philipp Hetkamp, and Walter Jentzen*
- 39S Norepinephrine Transporter as a Target for Imaging and Therapy**  
*Neeta Pandit-Taskar and Shakeel Modak*
- 54S Somatostatin Receptor 2-Targeting Compounds**  
*Daan A. Smit Duijzentkunst, Dik J. Kwekkeboom, and Lisa Bodei*
- 61S Somatostatin Receptor Antagonists for Imaging and Therapy**  
*Melpomeni Fani, Guillaume P. Nicolas, and Damian Wild*
- 67S Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy**  
*Matthias Eiber, Wolfgang P. Fendler, Steven P. Rowe, Jeremie Calais, Michael S. Hofman, Tobias Maurer, Sarah M. Schwarzenboeck, Clemens Kratochwil, Ken Herrmann, and Frederik L. Giesel*
- 77S CXCR4 Ligands: The Next Big Hit?**  
*Annemiek M.E. Walenkamp, Constantin Lapa, Ken Herrmann, and Hans-Jürgen Wester*

- 83S Theranostics Using Antibodies and Antibody-Related Therapeutics**  
*Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, and Elisabeth G.E. de Vries*

- 91S Therapeutic Radiometals Beyond  $^{177}\text{Lu}$  and  $^{90}\text{Y}$ : Production and Application of Promising  $\alpha$ -Particle,  $\beta^-$ -Particle, and Auger Electron Emitters**  
*Cristina Müller, Nicholas P. van der Meulen, Martina Benešová, and Roger Schibli*

- 97S Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?**  
*Uta Eberlein, Marta Cremonesi, and Michael Lassmann*

- 104S Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes**  
*F. Edward Boas, Lisa Bodei, and Constantinos T. Sofocleous*

## EDITORIAL BOARD

### Guest Editors

Ken Herrmann, MD, MBA  
University Hospital Essen  
Essen, Germany  
David Geffen School of Medicine at UCLA  
Los Angeles, California

Steven M. Larson, MD  
Memorial Sloan Kettering Cancer Center  
New York, New York

Wolfgang A. Weber, MD  
Memorial Sloan Kettering Cancer Center  
New York, New York

### Editor-in-Chief

Johannes Czernin, MD  
David Geffen School of Medicine at UCLA  
Los Angeles, California

Opinions expressed in the contributions to this supplement are solely those of the authors and do not necessarily reflect those of *The Journal of Nuclear Medicine* or the Society of Nuclear Medicine and Molecular Imaging. The journal, however, invites and welcomes different opinions in order to initiate and stimulate discussion.